aki

Lacidipine (SN-305) is a lipophilic dihydropyridine calcium antagonist with an intrinsically slow onset of activity. Due to its long duration of action, lacidipine does not lead to reflex tachycardia. It displays specificity in the vascular smooth muscle, where it acts as an antihypertensive agent to dilate peripheral arterioles and reduce blood pressure.

AKI-001 is a potent Aurora kinase inhibitor, which exhibits low nanomolar potency against both Aurora A and Aurora B enzymes, excellent cellular potency (IC50 < 100 nM), and good oral bioavailability. Phenotypic cellular assays show that both Aurora A and Aurora B are inhibited at inhibitor concentrations sufficient to block proliferation. Importantly, the cellular activity translates to potent inhibition of tumor growth in vivo. An oral dose of 5 mg kg QD is well tolerated and results in near stasis (92% TGI) in an HCT116 mouse xenograft model.

Anakinra (Raleukin) is a cytokine inactivator and interleukin 1 receptor antagonist that can be used to study secondary phagocytic lymphohistiocytosis and rheumatoid arthritis.

Terlakiren (CP-80,794) is an orally active, potent renin inhibitor used in the study of neurological disorders related to hypertension.

Tetrakis (4-carboxyphenyl) porphyrin (TCPP) serves as a metal remover and is a fabricated three-dimensional Ru polymer complex that can be grafted on SiO2/Nb2O5 substrate and subsequently metallized to study catalytic oxidation of hydrazine.

Jasplakinolide(Jaspamide), a naturally occurring cyclic peptide from marine sponges, is a potent inducer of actin polymerization.Jasplakinolide exhibits antifungal and antitumor activity and stabilizes pre-existing actin filaments. Jasplakinolide competitively binds to F-actin with the ghost pen cyclic peptide and has a Kd value of 15 nM for F-actin.

Takinib (EDHS-206) is a specific and effective TAK1 inhibitor(IC50= 9.5 nM).

AKI603 is a novel small molecule inhibitor of Aurora kinase A (AurA)(IC50 = 12.3 nM). AKI603 is developed to overcome resistance mediated by BCR-ABL-T315I mutation. AKI603 exhibits strong anti-proliferative activity in leukemic cells[1][2].

Kakisaponin A is a useful organic compound for research related to life sciences. The catalog number is T126551 and the CAS number is 1003864-78-5.

D-myo-Inositol-1,3,4,5-tetrakisphosphate potassium enhances extracellular calcium (Ca2+) influx by upregulating voltage-gated calcium channels.

Karakin is a group of plant growth regulators.

Locustakinin is a myotropic peptide.

Misakimycin is a mammalian cell growth stimulating substance produced by Streptomyces misakiensis BP-3621.

Makisterone A is an ecdysteroid that drives molting in insects. It binds the heterodimeric ecdysone receptor with nanomolar affinity.

2,4,5,6-Tetrakis(diphenylamino)isophthalonitrile is a useful organic compound for research related to life sciences and the catalog number is T64631.

4,4′,4″,4″′-(Porphine-5,10,15,20-tetrayl)tetrakis(benzenesulfonic acid) is a useful organic compound for research related to life sciences and the catalog number is T65464.

sodium tetrakis (pentafluorophenyl)-borate is a useful organic compound for research related to life sciences and the catalog number is T66574.

Octakis-(6-bromo-6-deoxy)-γ-cyclodextrin (catalog number T66647) is a valuable organic compound utilized in life sciences research.

Tetrakis[(S)-(+)-(1-adamantyl)-(N-phthalimido)acetato]dirhodium(II) is a useful organic compound for research related to life sciences. The catalog number is T67239 and the CAS number is 909389-99-7.

Ranakinin is a novel tachykinin receptor agonist; from the brain of frog, Rana ridibunda.

Canakinumab (ACZ885) is a recombinant human IL-1β-targeting monoclonal antibody that inhibits human and chorioallantoic monkey IL-1β with IC50 values of 43.6 and 40.8 pM, respectively. It exhibits anti-inflammatory activity by neutralizing IL-1β signaling, and it has been used for the treatment of gout and coronary artery disease.

1,1′,1′′,1′′′-[1,4-Piperazinediylbis(2,1-ethanediylnitrilo)]tetrakis[2-dodecanol], a lipid lipidoid, is used in the synthesis of lipid-based or lipidoid nanoparticles [1].

Contulakin G, an O-glycosylated invertebrate neurotensin, serves as a weaker agonist for the neurotensin receptor. Additionally, it is recognized as a potent antinociceptive agent [1] [2].

Clazakizumab, a monoclonal antibody, demonstrates high affinity and specificity towards the interleukin-6 (IL-6) cytokine, potentially inhibiting the cytokine response in COVID-19 caused by SARS-CoV-2. It is also under research for treating psoriatic arthritis (PsA) and renal antibody-mediated rejection [1] [2].